Compare Heron Therapeutics Inc (HRTX) vs Rocket Companies Inc. Class A Common Stock (RKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Rocket Companies Inc. Class A Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $74.18M), while Rocket Companies Inc. Class A Common Stock trades at $10.66 (market cap $30.67B). The key difference: Rocket Companies Inc. Class A Common Stock is far larger — about 413.5× Heron Therapeutics Inc's market cap, and Rocket Companies Inc. Class A Common Stock is more actively traded (41,104,143 versus 1,857,401). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 36 Days and Rocket Companies Inc. Class A Common Stock for 0 Days on average.
| HRTX | RKT | |
|---|---|---|
Market Cap | $74.18M | $30.67B |
Volume | 1,857,401 | 41,104,143 |
Sector | Health | Financials |
52-Week High | $1.49 | $23.44 |
52-Week Low | $0.27 | $10.53 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $180.92M | $60.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3906, down 6.02% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates. Despite a high gross margin of 70.07%, it posted a net loss of -$20.20 million in 2025. Analyst consensus is strongly positive with 17 buy ratings. Recent news highlights earnings results and competitive comparisons.
The outlook remains speculative given persistent losses and negative ROE, but strong analyst support and improving cash flow trends offer potential upside. Key risks include profitability challenges and revenue volatility. Investors should weigh the bullish sentiment against fundamental weaknesses.
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Rocket Companies Inc. Class A Common Stock
Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →
